BridgeBio Oncology Therapeutics Inc.

NASDAQ: BBOT · Healthcare · Biotechnology

PublicHQ South San Francisco, CA · San MateoCIK 0001869105Reports USD

#1 of 1,418 Healthcare companies by revenue

EA Score

——

FH 60DQ —GM —SS 46

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, Altman-Z · ↓ Piotroski F, listing tenure

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$134.0M

Employees

as of 2026-09-11

Market cap

$442.2M

as of 2026-09-11

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Net income-$134.0M-$134.0M2025

Operating income-$145.8M-$145.8M2025

Total assets$448.4M$448.4M2025

Liabilities$37.3M$37.3M2025

Equity$411.1M$411.1M2025

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is BridgeBio Oncology Therapeutics Inc.’s financial profile?

BridgeBio Oncology Therapeutics Inc. earned -$134.0M in FY2025 net income.

Peers · Healthcare

Vogenx Inc.——MapLight Therapeutics, Inc.——Cabaletta Bio, Inc.——Kyverna Therapeutics, Inc.——Rezolute, Inc.——PureTech Health plc——

Neighbors

San Mateo →

Meta Platforms, Inc.$201.0B86A Gilead Sciences, Inc.$29.4B87A Robinhood Markets, Inc.$4.5B67B Equinix, Inc.$9.2B74B Electronic Arts Inc.$7.5B82B+Revolution Medicines, Inc.$052D

Key facts

CEOPedro J. Beltran

SectorHealthcare

IndustryBiotechnology

HeadquartersSouth San Francisco, CA

ExchangeNASDAQ: BBOT

Employees88

IPO date2025-08-12

Latest filings

8-K2026-09-08 10-Q2026-08-11 8-K2026-08-11 8-K2026-06-22 8-K2026-05-12 10-Q2026-05-12 8-K2026-04-29 DEF 14A2026-04-28

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.